絞り込み

16643

広告

ノーベル化学賞の吉野さん 理事長務める大阪の研究施設に出勤

ノーベル化学賞に選ばれた吉野彰さんが、受賞決定後初めて、自身が理事長を務める大阪府内のリチウムイオン電池の研究施設に出勤し、研究への変わらぬ意欲を示しました。

  1. [医学] ICU患者への控えめな酸素供給...
  2. 移植不適格な新規診断多発性骨髄腫へのD-...
  3. 移植不適格な新規診断多発性骨髄腫に対して...
  4. 「イクメン企業アワード2019」・「イク...

ニュース一覧

Positive predictive value estimates for cell-free noninvasive prenatal screening from data of a large referral genetic diagnostic laboratory.

著者 Petersen AK , Cheung SW , Smith JL , Bi W , Ward PA , Peacock S , Braxton A , van den Veyver IB , Breman AM
Am J Obstet Gynecol.2017 Oct 12 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (35view , 0users)

Full Text Sources

Other Literature Sources

Since its debut in 2011, cell-free fetal DNA (cffDNA) screening has undergone rapid expansion with respect to both utilization and coverage. However, conclusive data regarding the clinical validity and utility of this screening tool, both for the originally included common autosomal and sex-chromosomal aneuploidies as well as the more recently added chromosomal microdeletion syndromes, has lagged behind. Thus, there is a continued need to educate clinicians and patients about the current benefits and limitations of this screening tool to inform pre and post-test counseling, pre/perinatal decision making and medical risk assessment/management.
PMID: 29032050 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード